Advertisement

International Journal of Clinical Pharmacy

, Volume 40, Issue 5, pp 1217–1224 | Cite as

Medication-related problems among adult chronic kidney disease patients in a sub-Saharan tertiary hospital

  • Lisper Wangeci NjeriEmail author
  • William Otieno Ogallo
  • David Gitonga Nyamu
  • Sylvia Adisa Opanga
  • Alfred Rugendo Birichi
Research Article
  • 131 Downloads

Abstract

Background

Chronic kidney disease (CKD) patients are prone to medication-related problems (MRPs). Few studies address the clinical relevance of MRPs among CKD patients in sub-Saharan Africa.

Objective

To investigate the frequency and predictors of MRPs among adult CKD patients treated at a tertiary care facility in an urban sub-Saharan setting.

Setting

Kenyatta National Hospital in Nairobi, Kenya.

Method

A cross-sectional study involving 60 adult patients with CKD was carried out. Data were collected through structured interviews and patient chart reviews between April 2016 and June 2016. MRPs identified from the collected data were classified according to Hepler and Strand classification. The frequencies of the identified MRPs were computed and logistic regression used to investigate the associations between the MRPs and covariates in the data. Main outcome measures: frequencies and predictors of MRPs.

Results

271 MRPs were identified. The commonest MRPs were drug interactions (21.8%), indication without drug (18.1%) and medication non-adherence (15.5%). Compared to patients with CKD stage 3, patients with CKD stage 4 were 5.9 times more likely to have an improper drug selection and 4.7 times more likely to experience overdosage. Other significant predictors of MRPs were the number of medications per prescription and the number of comorbidities per patient.

Conclusion

This study found a high frequency of MRPs among patients with chronic kidney disease receiving care in urban sub-Saharan tertiary hospital settings. The predictors of MRPs among CKD patients in this setting are likely to be multifactorial and include the CKD stage, polypharmacy, and comorbidities.

Keywords

Chronic kidney disease Medication-related problems Sub-Saharan Africa Tertiary hospital DRP Kenya 

Notes

Acknowledgements

We would like to acknowledge our participants at the Kenyatta National Hospital renal clinic and medical wards. Special thanks to respective matrons.

Funding

The study was partially funded by the Kenyatta National Hospital Research and Programs Department and the University of Nairobi. The funding organizations had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Conflicts of interest

The authors (all of them) declare that they have no conflict of interest.

Supplementary material

11096_2018_651_MOESM1_ESM.pdf (269 kb)
Supplementary material 1 (PDF 268 kb)

References

  1. 1.
    Couser WG, Remuzzi G, Mendis S, Tonelli M. The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int. 2011;80(12):1258–70.CrossRefGoogle Scholar
  2. 2.
    Schoolwerth AC, Engelgau MM, Hostetter TH, Rufo KH, Chianchiano D, McClellan WM, et al. Chronic kidney disease: a public health problem that needs a public health action plan. Prev Chronic Dis. 2006;3(2):A57-A.Google Scholar
  3. 3.
    World Kidney D. Chronic kidney disease: world kidney day; 2015. http://www.worldkidneyday.org/faqs/chronic-kidney-disease/. Accessed on 5th Oct 2016.
  4. 4.
    Centers for Disease, Prevention Ca. National chronic kidney disease fact sheet 2014 (1–4). http://www.cdc.gov/diabetes/pubs/factsheets/kidney.htm. Accessed on 12th July 2016.
  5. 5.
    Naicker S. Burden of end-stage renal disease in sub-Saharan Africa. Clin Nephrol. 2010;74(Suppl 1):S13–6.Google Scholar
  6. 6.
    Arogundade FA, Barsoum RS. CKD prevention in sub-Saharan Africa: a call for governmental, nongovernmental, and community support. Am J Kidney Dis. 2008;51(3):515–23.CrossRefGoogle Scholar
  7. 7.
    Cardone KE, Bacchus S, Assimon MM, Pai AB, Manley HJ. Medication-related problems in CKD. Adv Chronic Kidney Dis. 2010;17(5):404–12.CrossRefGoogle Scholar
  8. 8.
    Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm. 1990;47(3):533–43.PubMedGoogle Scholar
  9. 9.
    Belaiche S, Romanet T, Allenet B, Calop J, Zaoui P. Identification of drug-related problems in ambulatory chronic kidney disease patients: a 6-month prospective study. J Nephrol. 2012;25(5):782–8.CrossRefGoogle Scholar
  10. 10.
    Patel HR, Pruchnicki MC, Hall LE. Assessment for chronic kidney disease service in high-risk patients at community health clinics. Ann Pharmacother. 2005;39(1):22–7.CrossRefGoogle Scholar
  11. 11.
    Hassan Y, Al-Ramahi RJ, Aziz NA, Ghazali R. Impact of a renal drug dosing service on dose adjustment in hospitalized patients with chronic kidney disease. Ann Pharmacother. 2009;43:1598–605.CrossRefGoogle Scholar
  12. 12.
    Belaiche S, Romanet T, Bell R, Calop J, Allenet B, Zaoui P. Pharmaceutical care in chronic kidney disease: experience at Grenoble University Hospital from 2006 to 2010. J Nephrol. 2012;25(4):558–65.CrossRefGoogle Scholar
  13. 13.
    Marquito AB, Fernandes NMDS, Colugnati FAB, Paula RBD. Identifying potential drug interactions in chronic kidney disease patients. Jornal brasileiro de nefrologia: ʹorgão oficial de Sociedades Brasileira e Latino-Americana de Nefrologia. 2014;36(1):26–34.CrossRefGoogle Scholar
  14. 14.
    Rama M, Viswanathan G, Acharya LD, Attur RP, Reddy PN, Raghavan SV. Assessment of drug–drug interactions among renal failure patients of nephrology ward in a South Indian Tertiary Care Hospital; 2012, p. 63–8.Google Scholar
  15. 15.
    Stemer G, Lemmens-Gruber R. Clinical pharmacy activities in chronic kidney disease and end-stage renal disease patients: a systematic literature review. BMC Nephrol. 2011;12:35.CrossRefGoogle Scholar
  16. 16.
    Manley HJ, Cannella CA, Bailie GR, Peter WLS. Medication-related problems in ambulatory hemodialysis patients: a pooled analysis. Am J Kidney Dis. 2005;46(4):669–80.CrossRefGoogle Scholar
  17. 17.
    Manley HJ, McClaran ML, Overbay DK, Wright MA, Reid GM, Bender WL, et al. Factors associated with medication-related problems in ambulatory hemodialysis patients. Am J Kidney Dis. 2003;41(2):386–93.CrossRefGoogle Scholar
  18. 18.
    Magacho EJC, Ribeiro LC, Chaoubah A, Bastos MG. Adherence to drug therapy in kidney disease. Braz J Med Biol Res. 2011;44(3):258–62.CrossRefGoogle Scholar
  19. 19.
    Kenyatta National H. About Kenyatta National Hospital 2016. http://knh.or.ke/. Accessed on 5th Oct 2016.
  20. 20.
    Graffar M. Modern epidemiology; 1971. p. 661–9.Google Scholar
  21. 21.
    Daniel W. Biostatistics: a foundation for analysis in the health sciences (10th edition) 1999. 200–3 p. 978-1-118-30279-8.Google Scholar
  22. 22.
    Nyakiba JO, Kosgei RJ, Okalebo F. The extent of medication-related problems among patients at Kenyatta National Hospital Medical Wards: A 2012 Study: University of Nairobi; 2014.Google Scholar
  23. 23.
    Sumaili EK, Cohen EP, Zinga CV, Krzesinski J-M, Pakasa NM, Nseka NM. High prevalence of undiagnosed chronic kidney disease among at-risk population in Kinshasa, the Democratic Republic of Congo. BMC Nephrol. 2009;10:18.CrossRefGoogle Scholar
  24. 24.
    National Kidney F. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, clasification and stratification 2002. S1-S266 p. 1-931472-10-6.Google Scholar
  25. 25.
    Drug Interaction Checker (Internet). 2016 (cited 12th April 2016 to 15th July 2016). http://reference.medscape.com/drug-interactionchecker.
  26. 26.
    Team RC. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2014.Google Scholar
  27. 27.
    AbuRuz SM, Alrashdan Y, Jarab A, Jaber D, Alawwa IA. Evaluation of the impact of pharmaceutical care service on hospitalized patients with chronic kidney disease in Jordan. Int J Clin Pharm. 2013;35(5):780–9.CrossRefGoogle Scholar
  28. 28.
    Fraser SDS, Roderick PJ, May CR, McIntyre N, McIntyre C, Fluck RJ, et al. The burden of comorbidity in people with chronic kidney disease stage 3: a cohort study. BMC Nephrol. 2015;16(193–03):11p.Google Scholar
  29. 29.
    Khdour MR, Jarab AS, Adas HO, Samaro EZ, Mukattash TL, Hallak HO. Identification of drug-related problems: a prospective study in two general hospitals. Curr Clin Pharmacol. 2012;7(4):276–81.CrossRefGoogle Scholar
  30. 30.
    Fox CH, Swanson A, Kahn LS, Glaser K, Murray BM. Improving chronic kidney disease care in primary care practices: an upstate New York practice-based research network (UNYNET) study. J Am Board Family Med JABFM. 2008;21(6):522–30.CrossRefGoogle Scholar
  31. 31.
    Allen AS, Forman JP, Orav EJ, Bates DW, Denker BM, Sequist TD. Primary care management of chronic kidney disease. J Gen Intern Med. 2011;26(4):386–92.CrossRefGoogle Scholar
  32. 32.
    Onyango MA, Okalebo FA, Osanjo GO, Nyamu DG. Patterns of antibiotic use and dose adjustment in patients with chronic kidney disease at Kenyatta National Hospital, Kenya. Pharmacoepidemiol Drug Saf. 2013;22:485.Google Scholar
  33. 33.
    Liew Y, Ang S, Kamis HJ, Tan J, Brennan M. Medication compliance and understanding in pre-end stage renal disease. Nephrology. 2010;15:33–4.Google Scholar
  34. 34.
    Viswanathan M, Kahwati LC, Golin CE, Blalock SJ, Coker-Schwimmer E, Posey R, et al. Medication therapy management interventions in outpatient settings: a systematic review and meta-analysis. JAMA Intern Med. 2015;175(1):76–87.CrossRefGoogle Scholar
  35. 35.
    Barnes KD, Tayal NH, Lehman AM, Beatty SJ. Pharmacist-driven renal medication dosing intervention in a primary care patient-centered medical home. Pharmacotherapy. 2014;34(12):1330–5.CrossRefGoogle Scholar
  36. 36.
    Medication therapy management in pharmacy practice: core elements of an MTM service model (version 2.0). J Am Pharm Assoc JAPhA. 2008;48(3):341–53.Google Scholar
  37. 37.
    Isetts BJ, Schondelmeyer SW, Artz MB, Lenarz LA, Heaton AH, Wadd WB, et al. Clinical and economic outcomes of medication therapy management services: the Minnesota experience. J Am Pharm Assoc JAPhA. 2008;48(2):203–11 (3 p following 11).CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Pharmaceutics and Pharmacy Practice, School of PharmacyUniversity of NairobiNairobiKenya
  2. 2.Biomedical InformaticsColumbia UniversityNew YorkUSA
  3. 3.Department of Pharmaceutics and Pharmacy Practice, School of PharmacyUniversity of NairobiNairobiKenya
  4. 4.Department of PharmacyKenyatta National HospitalNairobiKenya

Personalised recommendations